**Gestational Age:**

| ≤ 28 weeks and 6 days | ≤ 12 months of age at the start of RSV season |

**CLD/CHD/Other:**

| Chronic lung disease of prematurity (CLDP) defined as gestational age ≤ 31 weeks and 6 days and a requirement for > 21% oxygen for at least 28 days after birth | ≤ 12 months of age at the start of RSV season  
OR  
≤ 24 months of age at the start of RSV season  
Continue to require medical support (supplemental oxygen, chronic corticosteroid or diuretic therapy) during 6 month period before the start of RSV season. |

| Hemodynamically significant congenital heart disease (CHD) | ≤ 12 months of age at start of RSV season  
OR  
≤ 24 months of age at the start of RSV season  
Cardiac transplantation during RSV season |

| Neuromuscular disorder or congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough | ≤ 12 months of age at start of RSV season |

| Immunocompromised due to chemotherapy or other conditions | ≤ 24 months of age at the start of RSV season  
Profundly immunocompromised during RSV season |

| Cystic Fibrosis (CF) | Recommended if ≤ 12 months of age at start of RSV season and at least one of the following indications are present:  
OR  
If ≤ 24 months of age at the start of RSV season with at least one of the following manifestations of severe lung disease:  
Weight for length less than the 10th percentile |

**Clinicians may administer up to a maximum of five monthly doses of Synagis (Palivizumab) during the RSV season to infants who qualify for prophylaxis in the first year of life. Qualifying infants born during the RSV season will require fewer doses**